What type of study is this?

This is a In Vitro Study study.

August 21, 2025Open Access

Figure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Co-targeting mcl-1 and bcl-xl significantly reduces cell viability in cancer models, enhancing treatment outcomes.
The study reports improved results using navitoclax and s63845 in various CRPC cell lines over a 48 to 72-hour period.
Assessment via CellTiter-Glo luminescent assay provided quantitative measures from multiple experiments to ensure reliability.
This approach may support the development of more effective therapies for patients with resistant prostate cancer.

Abstract

Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.

Figure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Abstract

Cite This Study

Also Consider

Also Consider